GlycoMimetics, Inc. GLYC was a big mover last session, as the company saw its shares rise nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 32.1% in the past one-month time frame.
The company has seen three positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for GlycoMimetics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
GlycoMimetics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
GlycoMimetics, Inc. Price
GlycoMimetics, Inc. Price | GlycoMimetics, Inc. Quote
Another player in the Medical sector is Akebia Therapeutics, Inc. AKBA, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is GLYC going up? Or down? Predict to see what others think: Up or Down.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlycoMimetics, Inc. (GLYC) : Free Stock Analysis Report
Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report
To read this article on Zacks.com click here.